GT200500358A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
GT200500358A
GT200500358A GT200500358A GT200500358A GT200500358A GT 200500358 A GT200500358 A GT 200500358A GT 200500358 A GT200500358 A GT 200500358A GT 200500358 A GT200500358 A GT 200500358A GT 200500358 A GT200500358 A GT 200500358A
Authority
GT
Guatemala
Prior art keywords
organic compounds
deposit formulations
preparation
pharmaceutical compositions
invention refers
Prior art date
Application number
GT200500358A
Other languages
English (en)
Inventor
Olivier Lambert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500358A publication Critical patent/GT200500358A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS LIQUIDAS, EN PARTICULAR A FORMULACIONES DE DEPOSITO QUE COMPRENDEN ANALOGOS DE SOMATOSTATINAS Y A UN PROCESO PARA LA PREPARACION DE ESTAS FORMULACIONES DE DEPOSITO.
GT200500358A 2004-12-22 2005-12-07 Compuestos organicos GT200500358A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428151.5A GB0428151D0 (en) 2004-12-22 2004-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
GT200500358A true GT200500358A (es) 2006-08-07

Family

ID=34113101

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500358A GT200500358A (es) 2004-12-22 2005-12-07 Compuestos organicos

Country Status (19)

Country Link
US (2) US20100029550A1 (es)
EP (1) EP1830806B1 (es)
JP (1) JP4977622B2 (es)
KR (1) KR101335757B1 (es)
CN (1) CN101072551B (es)
AR (1) AR051803A1 (es)
AU (1) AU2005318454B2 (es)
BR (1) BRPI0519209A2 (es)
CA (1) CA2585116C (es)
ES (1) ES2515097T3 (es)
GB (1) GB0428151D0 (es)
GT (1) GT200500358A (es)
MX (1) MX2007007572A (es)
PE (1) PE20060769A1 (es)
PL (1) PL1830806T3 (es)
PT (1) PT1830806E (es)
RU (1) RU2395274C2 (es)
TW (1) TW200637612A (es)
WO (1) WO2006066868A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
CN101883785B (zh) 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
CA2786181C (en) 2010-01-13 2017-12-12 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
US8535544B2 (en) 2010-07-26 2013-09-17 International Business Machines Corporation Structure and method to form nanopore
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
WO2018048609A1 (en) * 2016-09-06 2018-03-15 Monell Chemical Senses Center Method of regulating immunity in the intestines
MX2019010732A (es) * 2017-03-09 2019-11-01 Corcept Therapeutics Inc Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN118302211A (zh) * 2021-11-22 2024-07-05 Specgx有限责任公司 可注射缓释药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083305B1 (de) * 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
PT949905E (pt) 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
ATE432689T1 (de) * 2002-03-04 2009-06-15 Ipsen Pharma Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
JP5721624B2 (ja) * 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用

Also Published As

Publication number Publication date
BRPI0519209A2 (pt) 2009-01-06
KR101335757B1 (ko) 2013-12-02
CA2585116C (en) 2014-05-20
ES2515097T3 (es) 2014-10-29
GB0428151D0 (en) 2005-01-26
KR20070090942A (ko) 2007-09-06
PT1830806E (pt) 2014-11-24
WO2006066868A3 (en) 2006-10-12
EP1830806B1 (en) 2014-09-03
CA2585116A1 (en) 2006-06-29
AU2005318454A1 (en) 2006-06-29
WO2006066868A2 (en) 2006-06-29
US9303067B2 (en) 2016-04-05
CN101072551A (zh) 2007-11-14
PL1830806T3 (pl) 2015-03-31
JP2008524290A (ja) 2008-07-10
AU2005318454B2 (en) 2009-08-20
US20150038414A1 (en) 2015-02-05
JP4977622B2 (ja) 2012-07-18
RU2007128101A (ru) 2009-01-27
EP1830806A2 (en) 2007-09-12
US20100029550A1 (en) 2010-02-04
CN101072551B (zh) 2013-04-24
MX2007007572A (es) 2007-07-24
RU2395274C2 (ru) 2010-07-27
TW200637612A (en) 2006-11-01
PE20060769A1 (es) 2006-09-28
AR051803A1 (es) 2007-02-07

Similar Documents

Publication Publication Date Title
GT200500358A (es) Compuestos organicos
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
GT200900027A (es) Compuestos organicos
EA201170772A1 (ru) Органические соединения
CR10479A (es) Modulares bencimidazolicos de vr1
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CL2008001783A1 (es) Acido desoxicolico (dca); composicion farmaceutica que lo comprende; procedimiento de preparacion de acido desoxicolico; compuestos intermediarios, utiles en la preparacion de un medicamento para remover depositos de grasa.
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UY31457A1 (es) Derivados acidos de cicloalquilamino
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
UY29510A1 (es) Derivados de urea, metodos para su fabricación, y usos de los mismos
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
HN2009003296A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
UY30865A1 (es) Nuevos analogos de piridina x 161
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
CL2008001325A1 (es) Compuestos derivados de pirazol-piridinona; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar inflamacion, enfermedad de paget, osteoartritis, alzheimer, entre otras enfermedades.
BRPI1014887A8 (pt) composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan